New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Search
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
Digital Therapeutic
Digital Therapeutic
Strategic-collaboration-with-EnaraBio
Boehringer Ingelheim and Enara Bio enter strategic collaboration and licensing agreement to discover novel shared antigens for cancer immunotherapies.
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
Partnering Approach Video 2023
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
EMPA-KIDNEY trial early stop due to positive efficacy
EMPA-KIDNEY, the largest SGLT2 inhibitor trial in chronic kidney disease, will stop early due to clear evidence of positive efficacy
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Sharing knowledge from our medical device development
Why do we share some of our work beyond Boehringer for free?
History of Cats
From the African wildcat to the domesticated house cat of today, the fascinating journey and history of the cat touches almost all corners of the world.
The Angels Initiative
The Angels Initiative helps hospitals around the world become ‘stroke-ready’ so that stroke patients can be treated as quickly and effectively as possible.
How fast can a cheetah run wild and free?
Cheetahs’ top speed can reach up to 120km/h. But habitat loss, illegal wildlife trade and hunting made these impressive animals critically endangered.
Our people
Ambition. Passion. Integrity. Commitment. Empathy. Individuality. We expect these qualities at all levels.
Transboundary animal diseases (TADs)
Avian influenza? Bluetongue virus? FMD? Learn what are transboundary animal diseases and how they can impact us
Stroke Prevention in AF
Stroke Prevention in AF
International Women’s Day: gender and health equity
On International Women’s Day, we join forces to collectively strive for gender and health equity, empowering women in and beyond our company.
New study paves the way for liver cirrhosis treatments
The ADVANCE study will be the most detailed observational study of its kind providing a detailed analysis of liver health.
collaboration-LIBD
Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
IL-11 inhibitor antibody clinical development launched
Boehringer Ingelheim has launched clinical development of its first-in-class IL-11 inhibitor antibody as a fibrotic disease treatment
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Global Top Employer 2023
Global Top Employer 2023